Stocks Health care INTI
OTC · Health careInhibitor Therapeutics, Inc. (INTI)
It posted a net loss of $3.3M. At June 30, 2026 it held $515.8K in cash against $47.8K of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
Watch INTI in 60 secondsWhat Inhibitor Therapeutics, Inc. does
Inhibitor Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker INTI.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$3.3M | -$0.02 | n/a |
| 2024 | n/a | -$3.3M | -$0.02 | n/a |
| 2023 | n/a | -$3M | -$0.02 | n/a |
| 2022 | n/a | $12.1M | $0.03 | n/a |
| 2021 | $0 | -$298.6K | $0.00 | n/a |
| 2020 | $0 | -$1.1M | $0.00 | n/a |
Full financial statements: income, balance sheet and cash flow
Dividends
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2020 | n/a | $0 | n/a |
| 2019 | n/a | $99.2K | n/a |
Latest SEC filings
What Inhibitor Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 18, 2026
- August 17, 2026Proxy statement DEF 14A
- August 14, 2026
- May 15, 2026
- April 1, 2026
- April 1, 2026Other event 8-K
- March 26, 2026
- February 24, 2026
- November 13, 2025
- October 27, 2025
Insider trades
What the people running Inhibitor Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 1 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| July 1, 2026 | Black Robe Capital LLCOfficer, 10% owner | Gave as a gift | 3,200,000 | - |
| May 5, 2026 | Vasisht NirajDirector | Received as pay | 50,000 | - |
| May 4, 2026 | Odonnell Francis E JrChief Executive Officer, Director, 10% owner | Received as pay | 50,000 | - |
| May 4, 2026 | Sears Samuel P JrDirector | Received as pay | 50,000 | - |
| May 4, 2026 | Yanez MichelleDirector | Received as pay | 50,000 | - |
| May 4, 2026 | Osman Ronald EDirector, 10% owner | Received as payindirect | 50,000 | - |
| May 4, 2026 | Jerman Michael AllenDirector | Received as pay | 50,000 | - |
Who owns INTI
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
Largest institutional holders
Insiders
7 insiders reported holding 46,497,267 shares in total, about $4.6M at the last price.
| Holder | Shares |
|---|---|
| Osman Ronald EDirector, 10% owner | 23,614,98523,614,985 held indirectly |
| Black Robe Capital LLCOfficer, 10% owner | 19,901,057 |
| Sears Samuel P JrDirector | 1,229,543 |
| Yanez MichelleDirector | 1,221,271 |
| Vasisht NirajDirector | 200,000 |
| Jerman Michael AllenDirector | 180,411 |
| Odonnell Francis E JrChief Executive Officer, Director, 10% owner | 150,000 |
Questions about INTI
What does Inhibitor Therapeutics, Inc. do?
Inhibitor Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker INTI.
Is Inhibitor Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $3.3M.
When did Inhibitor Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the executive or director change from September 18, 2026.
Similar companies
Compare INTI with
Follow INTI
Get an email when Inhibitor Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow INTI: get an email when it filesWhere the numbers come from
Financial figures are the values Inhibitor Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.